Xilio Therapeutics

XLO

Market cap $37.1M

Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden  Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index Anticipate cash runway into the first quarter of 2027 WALTHAM, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2025.

Xilio Therapeutics, Inc. ( XLO ) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC November 10, 2025 4:30 PM EST Company Participants Ruth du Moulin Rene Russo - President, CEO & Director Katarina Luptakova - Chief Medical Officer Christopher Frankenfield - CFO & COO Conference Call Participants Diwakar Davar Aparna Parikh Daina Graybosch - Leerink Partners LLC, Research Division Marc Frahm - TD Cowen, Research Division Presentation Operator Good afternoon, and thank you for joining Xilio Therapeutics conference call and webcast. [Operator Instructions] I would now like to turn the call over to Ruth du Moulin from Xilio Therapeutics.

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB)

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, show potential for ctDNA as an early predictor for response to treatment with vilastobart in combination with atezolizumab in patients with MSS mCRC WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data across its portfolio, including preclinical data highlighting the best-in-class potential for Xilio's masked T cell engager platform and programs, as well as Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, and Phase 2 data related to circulating tumor DNA (ctDNA) for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4.

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective November 1, 2025, the company granted a non-qualified stock option to purchase 5,700 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a late-breaking poster presentation for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 5-9, 2025 in National Harbor, Maryland.

WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced multiple upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 6-9, 2025 at the Gaylord National Convention Center in National Harbor, Maryland.

WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2025, the company granted non-qualified stock options to purchase 26,000 shares of its common stock to three new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of patient dosing in Phase 2 of an ongoing Phase 1/2 clinical trial evaluating efarindodekin alfa (XTX301), a tumor-activated IL-12, as a monotherapy in patients with certain advanced solid tumors.